Document Detail

Long-term treatment with recombinant insulin-like growth factor 1 (IGF-1) in a child with IGF-1 gene mutation.
MedLine Citation:
PMID:  19517134     Owner:  NLM     Status:  MEDLINE    
We assessed the efficacy and safety of recombinant human insulin-like growth factor 1 (IGF-1) therapy over a period of 7.5 years in a child with severe IGF-1 deficiency. Recombinant human IGF-1 was administered subcutaneously in doses between 40 and 80 microg/kg once daily. Height velocity increased from 2 cm/year on average at baseline to 7.9 cm/year during the first year of treatment. In the following years, growth velocity was less but satisfactory during treatment, but decreased when therapy was stopped.
Daniela Concolino; Gianluca Muzzi; Simona Sestito; Giovanna Vega; Giuseppe Bonapace; Pietro Strisciuglio
Related Documents :
18676554 - Growth characteristics of infantile hemangiomas: implications for management.
18540254 - Response to growth hormone treatment and final height in noonan syndrome in a large coh...
24998984 - Preoperative atrial fibrillation is an independent predictor of worse early and late ou...
19264574 - Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreot...
25156854 - Conventional radiofrequency catheter ablation compared to multi-electrode ablation for ...
18000724 - Intragastric balloon insertion increases the frequency of erosive esophagitis in obese ...
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2009-06-11
Journal Detail:
Title:  European journal of pediatrics     Volume:  169     ISSN:  1432-1076     ISO Abbreviation:  Eur. J. Pediatr.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2009-12-24     Completed Date:  2010-03-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7603873     Medline TA:  Eur J Pediatr     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  245-7     Citation Subset:  IM    
Department of Pediatrics, University Magna Graecia of Catanzaro, c/o Ospedale Civile A. Pugliese, 88100 Catanzaro, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
DNA / genetics*
DNA Mutational Analysis
Follow-Up Studies
Injections, Subcutaneous
Insulin-Like Growth Factor I / administration & dosage*,  deficiency,  genetics*
Laron Syndrome / blood,  drug therapy*,  genetics
Recombinant Proteins / administration & dosage*
Time Factors
Reg. No./Substance:
0/Recombinant Proteins; 67763-96-6/Insulin-Like Growth Factor I; 9007-49-2/DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Structural changes in the epithelium of the small intestine and immune cell infiltration of enteric ...
Next Document:  Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival i...